Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 15/20 | 0.55 |
| ▸ | CCKAR | P32238 | 10/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.52 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900193 | 0.88 | CCKBR (0.64) | CCKBRCCKAR | |
| SCHEMBL17051376 | 0.86 | BRD4 (0.61) | CCKBRCCKARNOTCH1RBPJ | |
| SCHEMBL11900064 | 0.83 | CCKBR (0.57) | CCKBRCCKAR | |
| SCHEMBL4819173 | 0.83 | MEN1 (0.69) | CCKBRCCKARCHRM1 | |
| SCHEMBL2930364 | 0.82 | CCKBR (0.76) | CCKBRCCKAR | |
| SCHEMBL18394473 | 0.82 | CCKBR (0.76) | CCKBRCCKAR | |
| SCHEMBL18394863 | 0.82 | CCKBR (0.76) | CCKBRCCKAR | |
| SCHEMBL643084 | 0.82 | CCKBR (0.71) | CCKBRCCKAR | |
| SCHEMBL17044707 | 0.81 | NOTCH1 (0.72) | NOTCH1RBPJ | |
| SCHEMBL17044704 | 0.81 | NOTCH1 (0.72) | NOTCH1RBPJ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897946-B1 | N-SUBSTITUTED BIS(FLUOROALKKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9242940-B2 | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150246892-A1 | N-SUBSTITUTED BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246892-A1 | N-SUBSTITUTED BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, CNKSR1 | CCKBR 407/4885CCKAR 221/4885CHRM1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.